India, April 10 -- Biocon Biologics (BBL), a subsidiary of Biocon, today announced that the U.S. Food and Drug Administration (U.S. FDA) has approved Jobevne' (bevacizumab-nwgd), a biosimilar Bevacizumab for intravenous use. JOBEVNE, a recombinant humanized monoclonal antibody used to treat several different types of cancer, is a biosimilar to the reference product Avastin' (bevacizumab). JOBEVNE is a vascular endothelial growth factor (VEGF) inhibitor that binds with VEGF and blocks the interaction with its receptors to prevent angiogenesis - combating cancer by restricting blood supply to the tumor.The approval of JOBEVNE expands Biocon Biologics' biosimilar oncology portfolio in the United States, which also includes OGIVRI (Trastuzumab-...